- Home
- FORR vs YMAB Comparison
FORR vs YMAB Comparison
Compare FORR & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- YMAB
- Stock Information
- Founded
- FORR 1983
- YMAB 2015
- Country
- FORR United States
- YMAB United States
- Employees
- FORR N/A
- YMAB N/A
- Industry
- FORR Diversified Commercial Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FORR Consumer Discretionary
- YMAB Health Care
- Exchange
- FORR Nasdaq
- YMAB Nasdaq
- Market Cap
- FORR 179.6M
- YMAB 192.4M
- IPO Year
- FORR 1996
- YMAB 2018
- Fundamental
- Price
- FORR $10.63
- YMAB $4.60
- Analyst Decision
- FORR
- YMAB Buy
- Analyst Count
- FORR 0
- YMAB 11
- Target Price
- FORR N/A
- YMAB $17.55
- AVG Volume (30 Days)
- FORR 68.0K
- YMAB 226.0K
- Earning Date
- FORR 05-06-2025
- YMAB 05-13-2025
- Dividend Yield
- FORR N/A
- YMAB N/A
- EPS Growth
- FORR N/A
- YMAB N/A
- EPS
- FORR N/A
- YMAB N/A
- Revenue
- FORR $422,269,000.00
- YMAB $88,658,000.00
- Revenue This Year
- FORR N/A
- YMAB N/A
- Revenue Next Year
- FORR $2.04
- YMAB $16.03
- P/E Ratio
- FORR N/A
- YMAB N/A
- Revenue Growth
- FORR N/A
- YMAB 4.92
- 52 Week Low
- FORR $8.50
- YMAB $3.55
- 52 Week High
- FORR $20.62
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- FORR 55.44
- YMAB 56.43
- Support Level
- FORR $10.39
- YMAB $3.99
- Resistance Level
- FORR $10.91
- YMAB $5.00
- Average True Range (ATR)
- FORR 0.46
- YMAB 0.35
- MACD
- FORR 0.00
- YMAB 0.10
- Stochastic Oscillator
- FORR 67.59
- YMAB 70.47
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.